» Articles » PMID: 33467089

Pulling the Brakes on Fast and Furious Multiple Drug-Resistant (MDR) Bacteria

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Jan 20
PMID 33467089
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Life-threatening bacterial infections have been managed by antibiotics for years and have significantly improved the wellbeing and lifetime of humans. However, bacteria have always been one step ahead by inactivating the antimicrobial agent chemically or by producing certain enzymes. The alarming universal occurrence of multidrug-resistant (MDR) bacteria has compelled researchers to find alternative treatments for MDR infections. This is a menace where conventional chemotherapies are no longer promising, but several novel approaches could help. Our current review article discusses the novel approaches that can combat MDR bacteria: starting off with potential nanoparticles (NPs) that efficiently interact with microorganisms causing fatal changes in the morphology and structure of these cells; nanophotothermal therapy using inorganic NPs like AuNPs to destroy pathogenic bacterial cells; bacteriophage therapy against which bacteria develop less resistance; combination drugs that act on dissimilar targets in distinctive pathways; probiotics therapy by the secretion of antibacterial chemicals; blockage of quorum sensing signals stopping bacterial colonization, and vaccination against resistant bacterial strains along with virulence factors. All these techniques show us a promising future in the fight against MDR bacteria, which remains the greatest challenge in public health care.

Citing Articles

Recent developments in preventing catheter-related infections based on biofilms: A comprehensive review.

So B, Kim J, Jo J, So H Biomicrofluidics. 2024; 18(5):051506.

PMID: 39397894 PMC: 11470810. DOI: 10.1063/5.0195165.


Prevalence of multi-drug resistant bacteria in intensive care units at Tripoli University Hospital, Tripoli, Libya.

Ibrahim K, Thwood D, ELgheriani H, Salem M, Elgadiym Z, Zaghdani A Libyan J Med. 2024; 19(1):2348235.

PMID: 38718270 PMC: 11080667. DOI: 10.1080/19932820.2024.2348235.


Anti-Biofilm Strategies: A Focused Review on Innovative Approaches.

Iaconis A, De Plano L, Caccamo A, Franco D, Conoci S Microorganisms. 2024; 12(4).

PMID: 38674584 PMC: 11052202. DOI: 10.3390/microorganisms12040639.


Antibiotic resistance in patients with liver cirrhosis: Prevalence and current approach to tackle.

Liakina V World J Clin Cases. 2023; 11(31):7530-7542.

PMID: 38078132 PMC: 10698443. DOI: 10.12998/wjcc.v11.i31.7530.


Innovative Phospholipid Carriers: A Viable Strategy to Counteract Antimicrobial Resistance.

Nicolosi D, Petronio Petronio G, Russo S, Di Naro M, Cutuli M, Russo C Int J Mol Sci. 2023; 24(21).

PMID: 37958915 PMC: 10648799. DOI: 10.3390/ijms242115934.


References
1.
Kumar M, Curtis A, Hoskins C . Application of Nanoparticle Technologies in the Combat against Anti-Microbial Resistance. Pharmaceutics. 2018; 10(1). PMC: 5874824. DOI: 10.3390/pharmaceutics10010011. View

2.
Zharov V, Mercer K, Galitovskaya E, Smeltzer M . Photothermal nanotherapeutics and nanodiagnostics for selective killing of bacteria targeted with gold nanoparticles. Biophys J. 2005; 90(2):619-27. PMC: 1367066. DOI: 10.1529/biophysj.105.061895. View

3.
Wang J, Hu B, Xu M, Yan Q, Liu S, Zhu X . Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum beta-lactamase-producing Escherichia coli bacteremia. Int J Mol Med. 2006; 17(2):347-55. View

4.
Leuzzi R, Adamo R, Scarselli M . Vaccines against Clostridium difficile. Hum Vaccin Immunother. 2014; 10(6):1466-77. PMC: 5396221. DOI: 10.4161/hv.28428. View

5.
Esmaeillou M, Zarrini G, Rezaee M, Shahbazi Mojarrad J, Bahadori A . Vancomycin Capped with Silver Nanoparticles as an Antibacterial Agent against Multi-Drug Resistance Bacteria. Adv Pharm Bull. 2017; 7(3):479-483. PMC: 5651071. DOI: 10.15171/apb.2017.058. View